ATE453391T1 - Östrogene mittel enthaltende arzneizusammensetzungen - Google Patents

Östrogene mittel enthaltende arzneizusammensetzungen

Info

Publication number
ATE453391T1
ATE453391T1 AT01950781T AT01950781T ATE453391T1 AT E453391 T1 ATE453391 T1 AT E453391T1 AT 01950781 T AT01950781 T AT 01950781T AT 01950781 T AT01950781 T AT 01950781T AT E453391 T1 ATE453391 T1 AT E453391T1
Authority
AT
Austria
Prior art keywords
compositions containing
medicinal compositions
estrogenic agents
containing estrogenic
agents
Prior art date
Application number
AT01950781T
Other languages
English (en)
Inventor
Eric Benjamin
Wendy Dulin
Jiwaji Suryawanshi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE453391T1 publication Critical patent/ATE453391T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01950781T 2000-07-06 2001-06-29 Östrogene mittel enthaltende arzneizusammensetzungen ATE453391T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21619200P 2000-07-06 2000-07-06
PCT/US2001/020993 WO2002003987A2 (en) 2000-07-06 2001-06-29 Pharmaceutical compositions of estrogenic agents

Publications (1)

Publication Number Publication Date
ATE453391T1 true ATE453391T1 (de) 2010-01-15

Family

ID=22806095

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01950781T ATE453391T1 (de) 2000-07-06 2001-06-29 Östrogene mittel enthaltende arzneizusammensetzungen

Country Status (26)

Country Link
US (2) US20020031548A1 (de)
EP (1) EP1309327B1 (de)
JP (1) JP2004502733A (de)
KR (2) KR100894027B1 (de)
CN (2) CN1450895A (de)
AR (1) AR029538A1 (de)
AT (1) ATE453391T1 (de)
AU (2) AU7174101A (de)
BR (1) BR0112242A (de)
CA (1) CA2415058A1 (de)
CY (1) CY1109915T1 (de)
DE (1) DE60140945D1 (de)
DK (1) DK1309327T3 (de)
EA (1) EA006386B1 (de)
ES (1) ES2336304T3 (de)
HU (1) HUP0301422A3 (de)
IL (2) IL153647A0 (de)
MX (1) MXPA02012891A (de)
NO (1) NO20030030L (de)
NZ (1) NZ523330A (de)
PL (1) PL204866B1 (de)
PT (1) PT1309327E (de)
SI (1) SI1309327T1 (de)
TW (1) TWI294777B (de)
WO (1) WO2002003987A2 (de)
ZA (1) ZA200301004B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75135C2 (en) * 2001-05-01 2006-03-15 Pfizer Prod Inc Dry granulation method for manufacturing pharmaceutical composition containing tetrahydronaphthalene-2-ol derivative and low dosage tablet compositions
RU2355397C2 (ru) * 2002-06-13 2009-05-20 Уайт Режимы лечения базедоксифеном
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
UA84046C2 (ru) * 2004-01-13 2008-09-10 Уайет Лечение остеопороза, ассоциированного с терапией ингибиторами ароматазы
PE20060676A1 (es) 2004-04-07 2006-07-24 Wyeth Corp Polimorfo cristalino de acetato de bazedoxifeno
BRPI0509257A (pt) * 2004-04-07 2007-09-11 Wyeth Corp polimorfo cristalino de acetato de bazedoxifeno, composição, processo para preparar um polimorfo e para aumentar a proporção de acetato de bazedoxifeno forma b em uma composição, métodos de tratar um mamìfero, cáncer de mama e uma mulher em pós-menopausa para um ou mais distúrbios vasomotores, de abaixar colesterol e de inibir perda óssea em um mamìfero e uso de um polimorfo
RU2006132181A (ru) * 2004-04-08 2008-05-20 Вайет (Us) Базедоксифен аскорбат в качестве селективного модулятора рецептора эстрогена
WO2005099677A1 (en) * 2004-04-08 2005-10-27 Wyeth Bazedoxifene acetate solid dispersion formulations
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN100358517C (zh) * 2004-09-28 2008-01-02 马晶 一种枸橼酸他莫昔芬口腔崩解片及其制备方法
EP1787642A1 (de) * 2004-11-10 2007-05-23 Teva Pharmaceutical Industries Ltd. Herstellungsverfahren für komprimierte, feste Dosierungsformen, gut geeignet für Gebrauch bei Medikamenten mit niedriger Wasserlöslichkeit und dadurch hergestellte komprimierte, feste Dosierungsformen
CA2587295A1 (en) * 2004-11-10 2006-05-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
KR20070116607A (ko) * 2005-03-31 2007-12-10 와이어쓰 Ｏ-데스메틸벤라팍신 및 바제독시펜의 조합 산물 및 이의용도
US20070003623A1 (en) * 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
AU2012275036B2 (en) * 2005-08-24 2016-05-19 Wyeth Llc Bazedoxifene acetate formulations and manufacturing process thereof
AR056471A1 (es) * 2005-08-24 2007-10-10 Wyeth Corp Formulaciones de acetato de bazedoxifeno
CA2677193C (en) * 2007-02-01 2015-06-30 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
US20110065751A1 (en) * 2007-10-16 2011-03-17 Pharmathen S.A. Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
WO2009146097A1 (en) * 2008-04-02 2009-12-03 Dr. Reddy's Laboratories Ltd. Raloxifene pharmaceutical formulations
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
EP2448562B1 (de) 2009-07-02 2013-11-06 Synthon B.V. Raloxifen-zusammensetzung
CA2775599A1 (en) 2009-10-27 2011-05-12 Wyeth Llc Bazedoxifene formulations with antioxidants
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US9486411B2 (en) 2012-06-05 2016-11-08 Takeda Pharmaceutical Company Limited Solid preparation
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
CN103006570B (zh) * 2012-10-08 2013-12-25 孙维会 一种阿佐昔芬速释微丸及其制备方法
CN106164066B (zh) 2014-02-13 2020-01-17 因赛特公司 作为lsd1抑制剂的环丙胺
BR112016018555B1 (pt) 2014-02-13 2024-01-23 Incyte Holdings Corporation Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016161069A1 (en) 2015-04-02 2016-10-06 Theravance Biopharma R&D Ip, Llc Combination dosage form of a mu opioid receptor antagonist and an opioid agent
ES2757948T3 (es) 2015-04-03 2020-04-30 Incyte Corp Compuestos heterocíclicos como inhibidores LSD1
CN110402244B (zh) 2015-08-12 2023-02-03 因赛特公司 Lsd1抑制剂的盐
WO2018010543A1 (zh) * 2016-07-11 2018-01-18 武汉朗来科技发展有限公司 一种用于口服固体制剂的复合崩解剂体系及含有该复合崩解剂体系的口服固体制剂
KR101683192B1 (ko) * 2016-10-20 2016-12-08 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당을 유효성분으로 포함하는 갱년기 증후군의 개선, 예방 또는 치료용 조성물
KR101683193B1 (ko) * 2016-10-20 2016-12-08 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당을 유효성분으로 포함하는 갱년기 증후군의 개선, 예방 또는 치료용 조성물
CN107951034B (zh) * 2017-12-01 2021-03-23 郑州拓洋生物工程有限公司 维生素泡腾制剂及其制备方法
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
RU2732291C1 (ru) * 2020-02-13 2020-09-15 Открытое акционерное общество "Фармстандарт-Лексредства" (ОАО "Фармстандарт-Лексредства") Лекарственный препарат на основе травы алтея лекарственного для лечения простудных и острых респираторных заболеваний
CN115526105B (zh) * 2022-10-09 2026-02-03 北部湾大学 一种基于多元快速迭代滤波分解法的刀具磨损预测方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3552727A (en) * 1968-09-18 1971-01-05 American Air Filter Co Gas scrubbing apparatus
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
JP3029742B2 (ja) * 1992-08-20 2000-04-04 株式会社東芝 画像補正装置
JPH0674903A (ja) * 1992-08-26 1994-03-18 Sumitomo Metal Ind Ltd 平板状被検出材の微小欠陥検出方法及び装置
FR2698788B1 (fr) 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
US5342133A (en) * 1992-12-23 1994-08-30 Hewlett-Packard Company Paper moving system for a printer/plotter
US5332727A (en) 1993-04-29 1994-07-26 Birkmayer U.S.A. Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
IL112746A (en) * 1994-03-02 1999-12-31 Lilly Co Eli Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
US5811120A (en) 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
EP1113013A1 (de) * 1995-02-28 2001-07-04 Eli Lilly & Company Benzothiophen Verbindungen, Zwischenprodukte, Zusammensetzungen und Methode
US5919800A (en) 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
DK0802183T3 (da) 1996-04-19 2002-02-04 American Home Prod Østrogenforbindelser
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
EA003937B1 (ru) 1997-10-15 2003-10-30 Уайт Новые арилоксиалкилдиалкиламины
AU5026599A (en) * 1998-07-23 2000-02-14 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation

Also Published As

Publication number Publication date
IL153647A0 (en) 2003-07-06
TWI294777B (en) 2008-03-21
EA200300122A1 (ru) 2003-06-26
CA2415058A1 (en) 2002-01-17
WO2002003987A3 (en) 2002-07-11
US7759386B2 (en) 2010-07-20
EP1309327A2 (de) 2003-05-14
JP2004502733A (ja) 2004-01-29
DE60140945D1 (de) 2010-02-11
PL204866B1 (pl) 2010-02-26
NO20030030L (no) 2003-03-03
KR20030023689A (ko) 2003-03-19
DK1309327T3 (da) 2010-04-26
WO2002003987A2 (en) 2002-01-17
EA006386B1 (ru) 2005-12-29
PL365875A1 (en) 2005-01-10
ZA200301004B (en) 2004-05-05
KR100862174B1 (ko) 2008-10-09
KR100894027B1 (ko) 2009-04-22
IL153647A (en) 2011-03-31
US20080269198A1 (en) 2008-10-30
AU2001271741B2 (en) 2006-10-19
BR0112242A (pt) 2003-06-24
CN101416949A (zh) 2009-04-29
KR20070110454A (ko) 2007-11-16
NZ523330A (en) 2005-07-29
NO20030030D0 (no) 2003-01-03
AR029538A1 (es) 2003-07-02
EP1309327B1 (de) 2009-12-30
CY1109915T1 (el) 2014-09-10
HUP0301422A2 (hu) 2003-09-29
CN1450895A (zh) 2003-10-22
ES2336304T3 (es) 2010-04-12
SI1309327T1 (sl) 2010-03-31
PT1309327E (pt) 2010-02-23
HUP0301422A3 (en) 2006-07-28
US20020031548A1 (en) 2002-03-14
MXPA02012891A (es) 2003-10-24
AU7174101A (en) 2002-01-21

Similar Documents

Publication Publication Date Title
ATE453391T1 (de) Östrogene mittel enthaltende arzneizusammensetzungen
NO20025450L (no) Ny farmasöytisk sammensetning
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
DE60019741D1 (de) Nanopartikelzusammensetzungen enthaltend eplerenon
ITMI20010748A0 (it) Composizioni farmaceutiche
DK1524266T3 (da) Farmaceutisk sammensætning
FI991485A0 (fi) Uusi farmaseuttinen koostumus
AR028291A1 (es) Formulaciones oftalmicas
ATE391531T1 (de) Schweisshemmende mittel
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
AR028087A1 (es) Composiciones cosmeticas
NO20026123L (no) Farmasöytiske sammensetninger
NO20031095D0 (no) Farmasöytiske sammensetninger
IS6021A (is) Lyfjasamsetningar sem innihalda sítalópram
AR027959A1 (es) Composiciones cosmeticas
ATE270107T1 (de) Ciclesonidhaltige wässrige arzneizusammensetzungen
DE60008839D1 (de) Duftstoff-Zusammensetzung
AR027981A1 (es) Composiciones cosmeticas
DE60108398D1 (de) Kristallin-therapeutisches mittel
NO20030946L (no) Medisinske sammensetninger
ATE403414T1 (de) Shampoozusammensetzungen
EE200200689A (et) Ravimkoostised
EP1413314A4 (de) Medizinische zusammensetzungen
DK200100203U4 (da) Farmaceutisk komposition indeholdende citalopram

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties